No Data
Insulet Adds Abbott's FreeStyle Libre 2 Plus to Omnipod 5's Compatibility Roster
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $269
Insulet's Strategic Advancements and Market Positioning Drive Buy Rating
Citi Research's 'SMID Value' Rec List – CHWY, FHN, PODD, and More
Insulet To Present At Wolfe Research Healthcare Conference; Webcast At 12:00 PM ET
Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.
No Data
No Data